Open Nav

Please submit your session questions in advance at

NoNO Inc.

  • Michael Tymianski, NoNO Inc.

NoNO Inc. is a privately held, Canadian biotech developing neurotherapeutics for acute and chronic CNS disease. Our lead product is in two Phase 3 acute stroke studies – ESCAPE NA-1 for endovascular stroke therapy patients in the hospital and FRONTIER for treatment of suspected stroke patients pre-hospital by paramedics. We have imminent pivotal data with our lead indication reading out in Q4 2019 followed by anticipated commercial launch in Q1 2021.

NA-1 is a first-in-class drug against a first-in-class target, PSD95, for the treatment of the leading cause of global neurological disability. The USFDA has granted Fast Track and Orphan designations. NoNO has a strong balance sheet and cash flow to achieve NDA clearance and to support R&D efforts for label expansion from acute to chronic CNS. We anticipate entering clinic for our first chronic CNS indication by the end of 2019.

  • Date:Tuesday, February 12
  • Time:10:45 AM - 11:00 AM
  • Room:Gramercy
  • Location:7th Floor
  • Session Type:Company Presentation
  • Company Presentation - Presentation Type:Privately Funded Company
  • Submission ID:23482
  • Goal for Presentation:Secure funding and partnerships for global commercialization
  • Company
  • Company HQ City:Toronto
  • Company HQ State:Ontario
  • Company HQ Country:Canada
  • Total Amount Raised to Date, in All Rounds:more than $140 million
  • Year Founded:2003
  • Main Therapeutic Focus:CNS/Neurological
  • Lead Product in Development:NA-1
  • Development Phase of Primary Product:Phase III
  • Additional Information/Comments:17 million people suffer a stroke each year globally, more than all dementias combined, including Alzheimer’s. Only 1 in 10 currently receive treatment, and only about 1 in 10 of those ever return to life as it was before. The socioeconomic consequences are enormous. According to the WHO, stroke is the leading cause of neurological disability, with a global burden of disease nearly ten times that caused by all other dementias put together. The need is urgent for therapies that are neuroprotective in the acute phase and promote neuroplasticity in the recovery phase. The recent string of 8 positive endovascular thrombectomy trials (EVT) since 2015 has validated patient selection criteria for stroke trials. Investigators from 7 of those successful EVT trials have brought their track record of success to our pivotal program.
Michael Tymianski
NoNO Inc.